Results 21 to 30 of about 12,338 (219)

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

Protein & Cell, 2018
Clinical success of the proteasome inhibitor established bortezomib as one of the most effective drugs in treatment of multiple myeloma (MM). While survival benefit of bortezomib generated new treatment strategies, the primary and secondary resistance of
Li Yang, Jing Chen, Xiaoyan Han, Enfan Zhang, Xi Huang, Xing Guo, Qingxiao Chen, Wenjun Wu, Gaofeng Zheng, Donghua He, Yi Zhao, Yang Yang, Jingsong He, Zhen Cai   +13 more
doaj   +1 more source

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group

Haematologica, 2020
New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce disease recurrence and treatment-related morbidity. The Children’s Oncology Group Phase III AAML1031 trial tested whether the addition of bortezomib to standard ...
Richard Aplenc, Soheil Meshinchi, Lillian Sung, Todd Alonzo, John Choi, Brian Fisher, Robert Gerbing, Betsy Hirsch, Terzah Horton, Samir Kahwash, John Levine, Michael Loken, Lisa Brodersen, Jessica Pollard, Susana Raimondi, Edward Anders Kolb, Alan Gamis   +16 more
doaj   +1 more source

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

Haematologica, 2014
Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various twice-weekly and once-weekly bortezomib dosing schedules.
María-Victoria Mateos, Sara Bringhen, Paul G. Richardson, Juan Jose Lahuerta, Alessandra Larocca, Albert Oriol, Mario Boccadoro, Ramón García-Sanz, Francesco Di Raimondo, Dixie-Lee Esseltine, Helgi van de Velde, Avinash Desai, Anil Londhe, Jesús F. San Miguel, Antonio Palumbo   +14 more
doaj   +1 more source

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma

, 2022
The development of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) is well recognised in multiple myeloma (MM).
Christopher Thompson (7899002), N O'Connor-Byrne (14138973), Siobhan Glavey (7896182), Philip Murphy (10045793), John Quinn (7898771), R Tudor (14138981)   +5 more
core  

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma

Translational Oncology, 2017
Increased levels of the nuclear export protein, exportin 1 (XPO1), were demonstrated in multiple myeloma (MM) patients. Targeting XPO1 with selinexor (the selective inhibitor of nuclear export; SINE compound KPT-330) demonstrates broad antitumor activity
Barbara Muz, Feda Azab, Pilar de la Puente, Yosef Landesman, Abdel Kareem Azab   +4 more
doaj   +1 more source

Bortezomib Suppresses Focal Adhesion Kinase Expression Via Interrupting Nuclear Factor-Kappa B

, 2011
Aims: Bortezomib is a potent proteasome inhibitor currently used to treat various malignancies with promising results. To explore the role of bortezomib in reducing cancer cell Migration and inducing apoptosis, we evaluated the effects of bortezomib on ...
KO, BO-SHENG;CHANG, TZU-CHING;CHEN, CHIEN- HUNG;LIU, CHIA-CHIA;KUO, CHENG-CHIN;HSU, CHIUN;SHEN, YING-CHUN;SHEN, TANG-LONG;SHYUE, SONG-KUN;LIOU, JUN-YANG, 柯博升;張孜菁;陳建宏;劉佳佳;郭呈欽;許駿;沈盈君;沈湯龍;徐松錕;劉俊揚   +1 more
core   +1 more source

Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types

Journal of Experimental & Clinical Cancer Research, 2010
Background Survivin is known playing a role in drug resistance. However, its role in bortezomib-mediated inhibition of growth and induction of apoptosis is unclear.
Chanan-Khan Asher A, Calinski Diane, Ling Xiang, Zhou Muxiang, Li Fengzhi   +4 more
doaj   +1 more source

BORTEZOMIB INDUCED SUBCONJUNCTIVAL HEMORRHAGE

, 2017
Many drugs are used in the treatment of multiple myeloma but Thalidomide, Lenalidomide, Bortezomib, dexamethasone and their combination remains the main stay of treatment. The molecular formula of bortezomib is C19H25BN4O4 and its chemical IUPAC name is [
Karthik S Udupa, Balaji Ommurugan, Navin Patil, Karthik Rao   +3 more
core   +2 more sources

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence

Health Science Reports, 2023
Background and Aims Nonsmall cell lung cancer accounts for over 85% of lung cancer incidences worldwide, and often has a poor prognosis. Proteasome inhibitors, such as bortezomib, have previously demonstrated evidence in preclinical and clinical models ...
Alethea Dasha Wenning Chua, Thirumeninathan Thaarun, Hui Yang, Ainsley Ryan Yan Bin Lee   +3 more
doaj   +1 more source